) and MD1 (Glaxo Wellcome PLC, Ware, U.K.)] and two dry powder systems [Diskhaler@ (Glaxo Wellcome) and Turbuhaler@ (Astra AB, Sodertalje, Sweden)]. Rates of asthma-related health care consumption and treatment outcomes associated with use of the different inhalers are unknown.
Introduction
Asthma is quite prevalent in New Zealand, and accounts for up to 4.5% of general practice consultations (1) . In a recent national population survey, 8 .5% of adults reported use of asthma medication in the previous 12 months (2) .
Guidelines for asthma management recommend titrated doses of inhaled corticosteroids as first-line treatment for the inflammatory component of asthma, use of betaagonists for symptomatic relief, and oral corticosteroids to treat severe acute exacerbations (3) . Treatment according to these guidelines is common practice in New Zealand where approximately 47% of patients with physician-diagnosed asthma have been reported to receive inhaled corticosteroid therapy, with 62% of these treated on a daily basis (4) . Four corticosteroid inhaler devices are available in New Zealand, of which two are aerosol delivery systems [the Autohaler@ (3M Healthcare Ltd, Loughborough, U.K.; 3M Pharmaceuticals (Australia Pty Ltd, Sydney, Australia) and metered dose inhaler, or MD1 (Glaxo Wellcome PLC, Ware, U.K.)] and two are dry powder systems [the Diskhaler@ (Glaxo Wellcome) and Turbuhaler@ (Astra AB, Sodertalje, Sweden)]. None of these inhaler devices is suitable for use in all asthma patients, and there is increasing evidence that the drug delivery system used is an important determinant of the efficacy of inhaled corticosteroid therapy (5) (6) (7) . However, the extent to which the potential inhaler device-related differences in efficacy shown in clinical studies influence actual primary health care consumption and prescribing practices in this country is unknown.
The aim of this retrospective analysis was to compare actual asthma-related prescription and health-care consultation patterns in a large general practice population for patients treated with each of the corticosteroid inhaler devices prescribed as first-line treatment. Mean daily doses of inhaled corticosteroids were determined by identifying the dosage instructions for each prescription, and calculating the daily dose for the period of the prescription.
If the prescription contained a range of dose directions, the minimum prescribed dose was recorded.
Mean daily doses of beta-agonists were calculated from prescribed quantities and dose strength, and averaged over the entire study period. Beta-agonist volumes were calculated as salbutamol-equivalent doses to compensate for the differing potency of the different beta-agonists. The dose relationship used to calculate relative terbutaline to salbutamol potency was 25O:lOO (10) (11) (12) . Mean oral steroid doses were also calculated from prescribed quantities and dose strength for the study period. Prescription data for prednisone and betamethasone were pooled for analysis because the latter agent comprised only 0.2% of the total number of oral steroid prescriptions identified.
A consultation was defined as asthma-related if a prescription for asthma medication, an inquiry about asthma, or a peak flow reading was recorded in the case notes.
Asthma-related prescription and consultation data were analysed in relation to the type of corticosteroid inhaler device prescribed. The data were also stratified according to age group to distinguish the potentially confounding effects of probable treatment differences in asthmatic children and adolescents and of chronic obstructive airways disease (COAD) in older patients. The age bands selected were under 6 years, 6-18 years, 19-49 years and 50 years and over. The data were analysed further in a subgroup of patients aged 1949 years who had received at least one inhaled corticosteroid prescription including a daily dose higher than 15OOpg.
Ethical consent for this study was obtained from the Otago Ethics Committee of the Southern Regional Health Authority.
STATISTICAL ANALYSIS
Most of the data used for this analysis were positively skewed rather than normally distributed, so Student's t-tests and one-way ANOVAs were not strictly valid. Alternative non-parametric tests were therefore used. The Mann-Whitney U-test is a non-parametric equivalent of the t-test, while the Kruskal-Wallis H-test can be used to test whether two or more independent samples come from the same population (13) . Skewness-adjusted confidence intervals were constructed using a transformation involving an estimate of the skewness of the sample and the appropriate critical value from the standard normal distribution (14) . Standard chi-squared tests were aiso used to compare proportions between two or more groups. The KruskalWallis H-test and the standard chi-squared test both use the chi-squared statistic, although it is caiculated in a different manner. All chi-squared statistics relating to proportions are the result of the standard chi-squared test while other chi-squared statistics are the result of the Kruskal-Wallis H-test.
Of the 128 585 patient records searched, 12 590 patients (9.8%) had been prescribed asthma-related medication in the previous 12 months. A total of 6582 patients (5.1%) were prescribed any type of inhaled corticosteroid device. Of these, 5704 patients (4.4%) were prescribed an Autohaler, Diskhaler; MD1 or Turbuhaler as their sole corticosteroid inhaler device during the study period. This data set included 86.7% of patients prescribed any corticosteroid inhaler device and 45.3% of those prescribed any asthma-related medication.
The age and sex distribution of the patient population according to the type of corticosteroid inhaie: device used is shown in Table 1 . The mean age of patients prescribed the Diskhaler was 7 years younger than that of the overall study population.
The relative proportions of patients prescribed each of the different corticosteroid inhaler devices by age group are shown in Fig. 1 . Table 2 presents the numbers of asthma-related primary health-care consultations and prescriptions for each of the corticosteroid inhaler types prescribed, which were highest in the MD1 group and lowest in the Autohaler group. Table 3 shows the mean daily inhaled corticosteroid dose prescribed for each device which was lowest for the Autohaler (569 lug day-'), followed by the Diskhaler (638 pg day-') and MD1 (655,~g day-'), and highest for the Turbuhaler (990,~~g day-') group. Fig. 2 describes the mean inhaled corticosteroid dose for each device subdivided according to age group.
The difference in inhaled corticosteroid dose according to the delivery system used was statistically significant for all age groups. Skewness-adjusted 95% confidence intervals presented in Fig. 3 show that the overall mean corticosteroid doses prescribed for the Turbuhaler were significantly greater than for the other devices. Table 3 shows the proportion of patients treated with beta-agonists according to the type of corticosteroid inhaler used, which was lowest in the Autohaler group and highest in the MD1 group. Skewness-adjusted 95% confidence intervals for patients prescribed a beta-agonist suggest that the mean daily salbutamol-equivalent dose was similar for the four corticosteroid inhaler groups, although the MD1 and Diskhaler confidence intervals did not overlap. Table 3 also includes the proportion of patients prescribed oral steroids in each of the inhaler device groups. There was no significant difference between cumulative oral steroid doses prescribed in the Autohaler, MD1 and Turbuhaler groups k*=1.7, df=2, P=O.433). However, the Kruskal-Wallis test and skewness-adjusted confidence intervals suggested that the mean oral steroid dose prescribed for patients using the Diskhaler was significantly lower than for the other corticosteroid inhaler groups.
A significantly greater proportion of patients aged 19-49 years in the Turbuhaler and Diskhaler groups (29 and 23%, respectively) than in the MD1 group (4%) received at least one inhaled corticosteroid prescription including a daily dose higher than 1500,~g (see Table 4 ). Only two patients were prescribed the Autohaler in this dose range, which was insufficient for analysis of mean daily dose. Comparison of the proportion of patients prescribed aerosol inhalers (3.7%) and dry powder inhalers (27.4%) at doses higher than 1500 pg day -' was statistically significantly different (x2=256.27, df= 1, P<O.OOl).
Discussion
This retrospective study compared asthma-related prescription and consultation data for four different corticosteroid inhaler devices in the general practice setting, where an estimated 96% of asthmatic patients in New Zealand are treated (15) . Data for analysis were collected from the computerized clinical records of a large patient population to provide more detailed information about asthma-prescribing patterns than could be obtained from traditional randomized controlled clinical trials.
Mean daily inhaled corticosteroid doses in our study population varied according to the type of inhaler device prescribed. The mean daily dose for the Turbuhaler at dose equivalence based on 25O:lOO microgram efficacy ratio for terbutaline to salbutamol was estimated to compensate for the differing potency of these beta-agonists (10-12).
990,ug was significantly higher than for other inhaler devices. Although the overall mean corticosteroid dose for the Diskhaler was similar to that of the MD1 and Autohaler, analysis of the prescription data by age group showed that the mean dose for the Diskhaler in adults aged 1949 years (904 pg day -') was almost as high as for patients in the same age group prescribed the Turbuhaler (1058pg day-'). The low total Diskhaler dose results from the significantly greater number of younger patients prescribed lower doses with this device.
Interestingly, our prescription data show a trend to higher prescribed doses of inhaled corticosteroid independent of inhaler type in older patients, who are also likely to have some degree of COAD associated with their asthma. As the data were analysed in broad age groups, specific comment for the nature of the apparent increase in corticosteroid dose relative to age in a continuous distribution is 1400, limited. This prescribing pattern is, however, of interest in view of the lack of evidence from controlled clinical trials of a clear therapeutic role for inhaled corticosteroids in the treatment of COAD (16) .
There are several possible reasons for the higher-dose dry-powder corticosteroid inhaler prescribing seen in our survey, including the higher dose presentations for these devices compared with the aerosol inhalers, the relative efficiency of the different devices and, in this country at least, advocacy of higher inhaled corticosteroid doses as first-line treatment of asthma in general. It is also possible that patients in this survey who were prescribed higher corticosteroid doses using the dry powder inhaler devices had more severe asthma and required higher corticosteroid doses to control their symptoms. However, as in controlled clinical trials, it is difficult to make a clear distinction between asthma severity and asthma control because commonly used parameters of efficacy do not allow these components to be clearly separated (17) . Moreover, in our study patients were not randomized to treatment.
The finding of significantly higher prescribed corticosteroid doses for the dry powder inhaler systems, in particular the Turbuhaler, was unexpected. There has been evidence from clinical studies suggesting improved drug delivery using the Turbuhaler (7, 18, 19) , so it might have been reasonable to expect the doses prescribed for the Turbuhaler to be proportionately lower instead of higher than those for the other inhaler devices. Evidence from randomized controlled studies of the relative potency of budesonide and beclomethasone when delivered by MD1 has previously suggested equivalent efficacy (20) (21) (22) . The dose relationship with Diskhaler is not as well defined, although equivalence with beclomethasone MD1 has been demonstrated (20, 21) .
Another unexpected finding was the relatively high proportion of adult patients in the Turbuhaler and Diskhaler groups who were regularly prescribed daily inhaled corticosteroid doses exceeding 1500,ug day-' (29 and 23%, respectively) in the absence of clear evidence of improved asthma control using any of these inhaler devices at higher doses (16, 17, (20) (21) (22) (23) (24) .
Only 73% of our asthmatic population overall had received beta-agonist prescriptions during the 12-month study period. A higher proportion of patients prescribed a corticosteroid MD1 received beta-agonist prescriptions than those prescribed an Autohaler or Turbuhaler, although the volume of beta-agonists prescribed was very similar for all treatment groups. Salbutamol-equivalent beta-agonist doses and oral steroid prescriptions were highest and lowest, respectively, in the Diskhaler group, and were clinically similar for the Autohaler, Turbuhaler and MD1 groups.
The extent to which these prescription figures reflect actual prescribing in response to optimal asthma control using inhaled corticosteroids as first-line treatment, failure of medical record keeping, or patient usage of beta-agonists prescribed before the survey period is unknown. The frequency of beta-agonist prescribing indicated here is Although it is difficult to draw any definitive conclusions from our research because of acknowledged methodological limitations, these asthma-related prescription and consultation data afford a valuable insight into actual drug prescribing for asthma in a large patient population. Our principal findings are that significantly higher corticosteroid doses are prescribed for the dry powder devices compared with the aerosol inhalers and that the doses prescribed increase with age irrespective of inhaler device. These prescribing patterns raise questions about the extent to which the results of traditional comparative clinical studies of these inhaler devices can be extrapolated to actual medication usage by patients and prescribing in everyday clinical practice.
High quality clinical databases of the type used in our survey are being increasingly advocated in the literature as an invaluable tool for 'reality-based' medical research (29) (30) (31) , enabling more accurate assessment of the relevance of clinical trial results to clinical practice. More targeted use of databases such as that held by the RNZCGP Research Unit is likely to provide important information for clinical decision-making and lead to more rational use of healthcare resources. Future asthma studies using this methodology could include analysis of prescription data for newer asthma medications, including fluticasone, which was not generally available in New Zealand at the time of this survey.
